Rituximab 100

Rituximab 100 mg Injection
Rituximab 100 mg Injection is a chimeric monoclonal antibody used in the treatment of certain cancers and autoimmune disorders. It targets the CD20 antigen present on the surface of B-lymphocytes, leading to their destruction. Rituximab is a key therapy in hematological malignancies and immunological conditions.
Product Details
Generic Name: Rituximab
Strength: 100 mg
Dosage Form: Injection (Sterile concentrate for solution for infusion)
Route of Administration: Intravenous (IV infusion)
Therapeutic Class: Monoclonal Antibody / Targeted Anticancer Agent
Indications
Rituximab 100 mg Injection is indicated for the treatment of:
Non-Hodgkin’s lymphoma (CD20-positive)
Chronic lymphocytic leukemia (CLL)
Rheumatoid arthritis (in combination with methotrexate)
Other CD20-positive B-cell disorders as prescribed
Mechanism of Action
Rituximab binds specifically to the CD20 antigen on B-lymphocytes. This binding induces B-cell lysis through immune-mediated mechanisms such as complement-dependent cytotoxicity and antibody-dependent cell-mediated cytotoxicity.
Key Benefits
Targeted therapy against CD20-positive B-cells
Proven efficacy in hematological malignancies
Can be used alone or in combination chemotherapy regimens
Widely accepted in global oncology and immunology protocols
Dosage & Administration
Dosage and infusion schedule are determined by the treating physician based on patient condition, body surface area, and treatment protocol. Administration must be done under strict medical supervision.
Storage Conditions
Store at 2°C to 8°C (Refrigerated)
Do not freeze
Protect from light
Precautions
For hospital and oncology center use only
Premedication may be required to reduce infusion-related reactions
Monitor patients during and after infusion
Use with caution in patients with active infections